Our goal is to bring new therapy to cancer’s most frequently mutated oncogenic target. Kestrel is discovering and developing new molecules to treat intractable cancers. We are starting with potent inhibitors of pan-oncogenic-RAS. We rely on exceptional science, and our focus, always, is on patients.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $40M